<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pentastarch (Hydroxyethyl starch 200/0.5; Pentaspan) (United States: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pentastarch (Hydroxyethyl starch 200/0.5; Pentaspan) (United States: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Pentastarch (Hydroxyethyl starch 200/0.5; Pentaspan) (United States: Not available): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F207907"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Plasma Volume Expander, Colloid</li></ul></div>
<div class="block adr drugH1Div" id="F12805815"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Angina pectoris, edema, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Anxiety, chills, dizziness, fatigue, headache, insomnia, malaise, paresthesia, shakiness</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight gain (temporary)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea, increased serum amylase, nausea</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Blood coagulation disorder, hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum bilirubin</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactoid reaction, anaphylaxis, hypersensitivity reaction (includes hypotension, urticaria, wheezing)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Weakness</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasal congestion</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Renal disease</p></div>
<div class="block coi drugH1Div" id="F12805661"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to hydroxyethyl starch or any component of the formulation; bleeding disorders; congestive heart failure where volume overload is a concern; oliguria or anuria not related to hypovolemia</p></div>
<div class="block war drugH1Div" id="F12805724"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding: Avoid use in patients undergoing open heart surgery in association with cardiopulmonary bypass. HES solutions have been associated with excess bleeding in these patients. If used in other patient populations, discontinue use of HES at the first sign of coagulopathy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Fluid overload: Administration can cause fluid overload; use with caution in patients at risk from overexpansion of blood volume (eg, very young patients, aged patients, or those with heart failure).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic: Large volumes of pentastarch may cause reduction in hemoglobin concentration, coagulation factors, and other plasma proteins due to hemodilution; coagulation may be impaired (eg, prolonged PT, PTT, and clotting times) and a transient prolongation of bleeding time may be observed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Anaphylactic/anaphylactoid reactions have been reported; discontinue use immediately with signs of hypersensitivity and administer appropriate therapy. Patients allergic to corn may be allergic to pentastarch.</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney failure: <b>HES solutions have been associated with kidney injury requiring renal replacement therapy in critically ill patients (Reinhart 2012); avoid use in critically ill adult patients, including those with sepsis and those admitted to the ICU. If used in patients who are not critically ill, avoid use in patients with preexisting kidney dysfunction and discontinue use at the first sign of kidney injury. </b> Since the need for renal replacement therapy has been reported up to 90 days after HES administration, continue to monitor renal function in all patients for at least 90 days.</p>
<p style="text-indent:-2em;margin-left:4em;">• Treatment-related mortality: <b>Avoid use in critically ill adult patients, including those with sepsis and those admitted to the ICU. HES solutions have been associated with an increased risk of mortality in the critically ill</b> (Brunkhorst 2008; Perel 2012; Perner 2012; SSC [Evans 2021]). Crystalloids (eg, sodium chloride and balanced solutions) are recommended as the fluid of choice for initial resuscitation and ongoing resuscitation (SSC [Evans 2021]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding disorders (eg, von Willebrand’s disease): Use caution in severe bleeding disorders; may increase the risk of more bleeding.</p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure: Use with caution in patients with heart failure; monitor closely for fluid overload.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with mild-to-moderate hepatic impairment. Avoid use in patients with severe hepatic impairment. May result in further reduction of coagulation factors in patients with ongoing hepatic impairment, increasing the risk of bleeding. Use with caution in patients with a history of liver disease due to elevations of indirect bilirubin (significance unknown).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; fluid status including urine output should be monitored closely. Use is contraindicated with oliguria or anuria not related to hypovolemia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Not a substitute for red blood cells or coagulation factors.</p></div>
<div class="block prod-avail drugH1Div" id="F12806126"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Not available in the US; All Canadian dosage forms have been discontinued for more than 1 year.</p></div>
<div class="block geq drugH1Div" id="F207889"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block use drugH1Div" id="F207896"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Not approved in the US</p>
<p style="text-indent:-2em;margin-left:2em;">Adjunctive treatment in the management of shock</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>The Surviving Sepsis Campaign International Guidelines for the Management of Sepsis and Septic Shock recommends <i>against</i> the use of hydroxyethyl starch (eg, pentastarch) for fluid resuscitation of sepsis and septic shock (SSC [Evans 2021]).</p></div>
<div class="block cyt drugH1Div" id="F13299845"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6222215"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Arbekacin: Pentastarch may enhance the nephrotoxic effect of Arbekacin. <i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F12805680"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were observed in animal reproduction studies.</p></div>
<div class="block brc drugH1Div" id="F12805681"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">Excretion in human breast milk is unknown; use caution.</p></div>
<div class="block mop drugH1Div" id="F12806093"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">BP, heart rate, central venous pressure, capillary refill time, cardiac index; if pulmonary artery catheter in place, monitor pulmonary capillary wedge pressure, systemic vascular resistance, and pulmonary vascular resistance; urine output, hemoglobin, hematocrit, serum electrolytes, kidney function (continue to monitor for at least 90 days after administration), coagulation parameters.</p></div>
<div class="block pha drugH1Div" id="F12805851"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Produces plasma volume expansion by virtue of its highly colloidal starch structure</p></div>
<div class="block phk drugH1Div" id="F12805853"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Volume expansion: Within 1 hour</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: 18-24 hours (improves hemodynamic status for 12-18 hours)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~2 days</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~70% within 24 hours; ~80% within 1 week)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58843914"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Hestar-200</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-18184958">
<a name="18184958"></a>Brunkhorst FM, Engel C, Bloos F, et al, "Intensive Insulin Therapy and Pentastarch Resuscitation in Severe Sepsis," <i>N Engl J Med</i>, 2008, 358(2):125-39.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentastarch-hydroxyethyl-starch-200-0-5-pentaspan-united-states-not-available-drug-information/abstract-text/18184958/pubmed" id="18184958" target="_blank">18184958</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34605781">
<a name="34605781"></a>Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021. <i>Crit Care Med</i>. 2021;49(11):e1063-e1143. doi:10.1097/CCM.0000000000005337<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentastarch-hydroxyethyl-starch-200-0-5-pentaspan-united-states-not-available-drug-information/abstract-text/34605781/pubmed" id="34605781" target="_blank">34605781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15966753">
<a name="15966753"></a>Jungheinrich C and Neff TA, "Pharmacokinetics of Hydroxyethyl Starch," <i>Clin Pharmacokinet</i>, 2005;44(7):681-99.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentastarch-hydroxyethyl-starch-200-0-5-pentaspan-united-states-not-available-drug-information/abstract-text/15966753/pubmed" id="15966753" target="_blank">15966753</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22696320">
<a name="22696320"></a>Perel P and Roberts I, “Colloids versus Crystalloids for Fluid Resuscitation in Critically Ill Patients,” <i>Cochrane Database Syst Rev</i>, 2012, 6:CD000567.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentastarch-hydroxyethyl-starch-200-0-5-pentaspan-united-states-not-available-drug-information/abstract-text/22696320/pubmed" id="22696320" target="_blank">22696320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22738085">
<a name="22738085"></a>Perner A, Haase N, Guttormsen AB, et al, “Hydroxyethyl Starch 130/0.4 versus Ringer’s Acetate in Severe Sepsis [published correction appears in <i>N Engl J Med</i>. 2012;367(5):481]. <i>N Engl J Med</i>. 2012;367(2):124-134.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentastarch-hydroxyethyl-starch-200-0-5-pentaspan-united-states-not-available-drug-information/abstract-text/22738085/pubmed" id="22738085" target="_blank">22738085</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22323076">
<a name="22323076"></a>Reinhart K, Perner A, Sprung CL, et al, “Consensus Statement of the ESICM Task Force on Colloid Volume Therapy in Critically Ill Patients,” <i>Intensive Care Med</i>, 2012, 38(3):368-83.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentastarch-hydroxyethyl-starch-200-0-5-pentaspan-united-states-not-available-drug-information/abstract-text/22323076/pubmed" id="22323076" target="_blank">22323076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28101605">
<a name="28101605"></a>Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. <i>Intensive Care Med</i>. 2017;43(3):304-377. doi: 10.1007/s00134-017-4683-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentastarch-hydroxyethyl-starch-200-0-5-pentaspan-united-states-not-available-drug-information/abstract-text/28101605/pubmed" id="28101605" target="_blank">28101605</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11896309">
<a name="11896309"></a>Strauss RG, Pennell BJ, and Stump DC, "A Randomized, Blinded Trial Comparing the Hemostatic Effects of Pentastarch Versus Hetastarch," <i>Transfusion</i>, 2002, 42(1):27-36.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pentastarch-hydroxyethyl-starch-200-0-5-pentaspan-united-states-not-available-drug-information/abstract-text/11896309/pubmed" id="11896309" target="_blank">11896309</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10203 Version 85.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
